[Combination chemotherapy with docetaxel and cisplatin in weekly schedule in the treatment of 30 cases of advanced non-small cell lung cancer].
To observe the response rate, survival time and toxicity of docetaxel and cisplatin in weekly schedule in the treament of stage III-IV non-small cell lung cancer. A total of 30 cases of stage III-IV non-small cell lung cancer was included in this study. Docetaxel 25 mg/m² and cisplatin 25 mg/m² were given through intravenous dripping for the 1st, 8th, and 15th days. The chemotherapy was repeated every 28 days. Each patient was given at least 2 cycles. The overall response rate was 43.3% (13/30,all were partial response). Quality of life of the patients was improved (there were 66.7% of the patients with Karnofsky score increased or unchanged). Median remission duration was 7 months. 40% of the patients survived for more than 1 year. The main toxicity was hematological: Grade III-IV leucopenia was 16.7%; Grade III thrombocytopenia was 6.7%. The non-hematological toxicity was mild. The regimen of docetaxel and cisplatin in weekly schedule is effective and tolerable in the treatment of non-small cell lung cancer.